Detalhe da pesquisa
1.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Lancet
; 394(10198): 576-586, 2019 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280967
2.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
N Engl J Med
; 375(5): 422-34, 2016 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27518661
3.
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
J Am Acad Dermatol
; 78(1): 90-99.e1, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993005
4.
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Dermatol Ther (Heidelb)
; 12(2): 561-575, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050485
5.
A brief guide to pustular psoriasis for primary care providers.
Postgrad Med
; 133(3): 330-344, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33118424
6.
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
J Am Acad Dermatol
; 61(1 Suppl 1): S1-S46, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19527820
7.
Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
J Dermatolog Treat
; 29(3): 220-229, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28792259
8.
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Cutis
; 79(4): 322-6, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17500381
9.
Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.
JAMA Dermatol
; 151(1): 87-94, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25471223
10.
Use of biologic agents in combination with other therapies for the treatment of psoriasis.
Am J Clin Dermatol
; 15(6): 467-78, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25373522
11.
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.
Dermatol Ther (Heidelb)
; 2(1): 1, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23205324
12.
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.
Dermatol Ther (Heidelb)
; 2(1): 2, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23205325